At the news
? NEUTRALIMPACT 5/10 425 filed Nov 9, 2026 at 21:49 ET
Ambros Therapeutics presented an Analyst Day deck detailing its pending reverse merger with Werewolf Therapeutics (HOWL), including a concurrent $150M PIPE co-led by RA Capital Management and Janus Henderson Investors. The combined company is valued at ~$697.5M pro forma, with Ambros implied at $500M and Werewolf at $47.5M. The deal is expected to close in Q4 2026, and the combined entity will trade as 'AMBX' with proceeds funding the CRPS-RISE pivotal trial of neridronate through NDA submission.
- Reverse triangular merger of Werewolf subsidiary into Ambros; Ambros survives as wholly owned subsidiary.
- Pro forma combined company value at closing: ~$697.5M.
- Implied valuation for Ambros: $500M (before concurrent PIPE).
- Implied valuation for Werewolf: $47.5M ($30M net cash + $17.5M Nasdaq listing value).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access